Morepen Laboratories Limited

The United States Food and Drug Administration (US FDA) has cleared Montelukast Sodium, a bulk drug/ API manufactured by Morepen Laboratories , for sale in the US market. This gives Morepen an entry into the ₹2,000-crore (approx. $300 million) US market for Montelukast. The first commercial orders for the bulk drug are expected in Q2 FY 2018-19. Shares of Morepen Labs jumped 20 per cent at ₹30.30 on the BSE.